Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia

Research output: Contribution to journalReview article

Abstract

Introduction: Juvenile myelomonocytic leukemia (JMML) is a clonal hematopoietic disorder of infancy/early childhood, resulting from oncogenic mutations in genes involved in the Ras pathway. As JMML often exhibits an aggressive course, the timing of diagnosis and treatment is critical to outcome. Areas covered: This review summarizes current approaches to diagnosis and treatment of JMML, highlighting most recent insights into genetic and epigenetic mechanisms underlying the disease, and providing an overview of novel potential therapeutic strategies. Expert commentary: At present, allogeneic HSCT remains the only potentially effective therapy, being able to cure more than 50% of patients, relapse representing the main cause of treatment failure. Prompt HSCT is recommended for all children with NF1, somatic PTPN11 and KRAS mutations, and for most children with somatic NRAS mutations. Conversely, a ‘watch and wait’ strategy should be adopted in children with germline CBL mutations, specific somatic NRAS mutation, and in Noonan syndrome patients, since spontaneous resolution has been reported to occur. Novel drugs targeting relevant nodes of JMML leukemogenesis have been explored in pre-HSCT window or at relapse. The use of 5-azacytidine, a DNA-hypomethylating agent reported to induce hematologic and molecular remission in some JMML children, is currently being investigated in clinical trials.

Original languageEnglish
Pages (from-to)129-143
Number of pages15
JournalExpert Review of Hematology
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Juvenile Myelomonocytic Leukemia
Mutation
Noonan Syndrome
Therapeutics
Azacitidine
Recurrence
Germ-Line Mutation
Drug Delivery Systems
Treatment Failure
Epigenomics
Clinical Trials
DNA
Genes

Keywords

  • 5-azacytidine
  • hematopoietic stem cell transplantation
  • juvenile myelomonocytic leukemia
  • myelodysplastic/myeloproliferative disorders
  • RAS pathway
  • targeted therapy

ASJC Scopus subject areas

  • Hematology

Cite this

@article{fb6945bb2bc74c1da028ff8c4b4bb9b4,
title = "Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia",
abstract = "Introduction: Juvenile myelomonocytic leukemia (JMML) is a clonal hematopoietic disorder of infancy/early childhood, resulting from oncogenic mutations in genes involved in the Ras pathway. As JMML often exhibits an aggressive course, the timing of diagnosis and treatment is critical to outcome. Areas covered: This review summarizes current approaches to diagnosis and treatment of JMML, highlighting most recent insights into genetic and epigenetic mechanisms underlying the disease, and providing an overview of novel potential therapeutic strategies. Expert commentary: At present, allogeneic HSCT remains the only potentially effective therapy, being able to cure more than 50{\%} of patients, relapse representing the main cause of treatment failure. Prompt HSCT is recommended for all children with NF1, somatic PTPN11 and KRAS mutations, and for most children with somatic NRAS mutations. Conversely, a ‘watch and wait’ strategy should be adopted in children with germline CBL mutations, specific somatic NRAS mutation, and in Noonan syndrome patients, since spontaneous resolution has been reported to occur. Novel drugs targeting relevant nodes of JMML leukemogenesis have been explored in pre-HSCT window or at relapse. The use of 5-azacytidine, a DNA-hypomethylating agent reported to induce hematologic and molecular remission in some JMML children, is currently being investigated in clinical trials.",
keywords = "5-azacytidine, hematopoietic stem cell transplantation, juvenile myelomonocytic leukemia, myelodysplastic/myeloproliferative disorders, RAS pathway, targeted therapy",
author = "Franco Locatelli and Mattia Algeri and Pietro Merli and Luisa Strocchio",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/17474086.2018.1421937",
language = "English",
volume = "11",
pages = "129--143",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia

AU - Locatelli, Franco

AU - Algeri, Mattia

AU - Merli, Pietro

AU - Strocchio, Luisa

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: Juvenile myelomonocytic leukemia (JMML) is a clonal hematopoietic disorder of infancy/early childhood, resulting from oncogenic mutations in genes involved in the Ras pathway. As JMML often exhibits an aggressive course, the timing of diagnosis and treatment is critical to outcome. Areas covered: This review summarizes current approaches to diagnosis and treatment of JMML, highlighting most recent insights into genetic and epigenetic mechanisms underlying the disease, and providing an overview of novel potential therapeutic strategies. Expert commentary: At present, allogeneic HSCT remains the only potentially effective therapy, being able to cure more than 50% of patients, relapse representing the main cause of treatment failure. Prompt HSCT is recommended for all children with NF1, somatic PTPN11 and KRAS mutations, and for most children with somatic NRAS mutations. Conversely, a ‘watch and wait’ strategy should be adopted in children with germline CBL mutations, specific somatic NRAS mutation, and in Noonan syndrome patients, since spontaneous resolution has been reported to occur. Novel drugs targeting relevant nodes of JMML leukemogenesis have been explored in pre-HSCT window or at relapse. The use of 5-azacytidine, a DNA-hypomethylating agent reported to induce hematologic and molecular remission in some JMML children, is currently being investigated in clinical trials.

AB - Introduction: Juvenile myelomonocytic leukemia (JMML) is a clonal hematopoietic disorder of infancy/early childhood, resulting from oncogenic mutations in genes involved in the Ras pathway. As JMML often exhibits an aggressive course, the timing of diagnosis and treatment is critical to outcome. Areas covered: This review summarizes current approaches to diagnosis and treatment of JMML, highlighting most recent insights into genetic and epigenetic mechanisms underlying the disease, and providing an overview of novel potential therapeutic strategies. Expert commentary: At present, allogeneic HSCT remains the only potentially effective therapy, being able to cure more than 50% of patients, relapse representing the main cause of treatment failure. Prompt HSCT is recommended for all children with NF1, somatic PTPN11 and KRAS mutations, and for most children with somatic NRAS mutations. Conversely, a ‘watch and wait’ strategy should be adopted in children with germline CBL mutations, specific somatic NRAS mutation, and in Noonan syndrome patients, since spontaneous resolution has been reported to occur. Novel drugs targeting relevant nodes of JMML leukemogenesis have been explored in pre-HSCT window or at relapse. The use of 5-azacytidine, a DNA-hypomethylating agent reported to induce hematologic and molecular remission in some JMML children, is currently being investigated in clinical trials.

KW - 5-azacytidine

KW - hematopoietic stem cell transplantation

KW - juvenile myelomonocytic leukemia

KW - myelodysplastic/myeloproliferative disorders

KW - RAS pathway

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85041204944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041204944&partnerID=8YFLogxK

U2 - 10.1080/17474086.2018.1421937

DO - 10.1080/17474086.2018.1421937

M3 - Review article

AN - SCOPUS:85041204944

VL - 11

SP - 129

EP - 143

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 2

ER -